<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615524</url>
  </required_header>
  <id_info>
    <org_study_id>VEG108843</org_study_id>
    <nct_id>NCT00615524</nct_id>
  </id_info>
  <brief_title>Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the efficacy and safety of exemestane alone or in&#xD;
      combination with pazopanib in postmenopausal women who have hormone receptor positive breast&#xD;
      cancer and have failed therapy with tamoxifen, anastrazole or letrozole.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Cancelled Before Enrollment&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability Overall response rate (complete and partial responses) in subjects with measurable disease Overall survival Change in health-related quality of life (HRQL) relative to baseline Biomarkers</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Hormone-receptor Positive Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane and pazopanib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have measurable disease OR must be evaluable for disease progression&#xD;
&#xD;
          -  Age &gt;/= 18 years.&#xD;
&#xD;
          -  Postmenopausal women&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.&#xD;
&#xD;
          -  Histologically or cytologically confirmed ER and/or PgR positive carcinoma of the&#xD;
             breast with unresectable, locally advanced and/or metastatic disease&#xD;
&#xD;
          -  Subjects must have received prior hormonal therapy for the treatment of breast cancer&#xD;
             (anastrozole, letrozole, or tamoxifen)&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of exemestane or pazopanib&#xD;
&#xD;
          -  Premenopausal women&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is&#xD;
             progressing in severity.&#xD;
&#xD;
          -  Prior therapy with a VEGF inhibitor.&#xD;
&#xD;
          -  Use of an investigational agent, including an investigational anti-cancer agent,&#xD;
             within 28 days or 5 half-lives, whichever is longer, prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Evidence of recurrence or active disease from prior malignancy.&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             GI bleeding or affect the absorption of the investigational product(s).&#xD;
&#xD;
          -  Presence of uncontrolled infection.&#xD;
&#xD;
          -  History of any major cardiovascular conditions within the past 6 months:&#xD;
&#xD;
          -  Poorly controlled hypertension&#xD;
&#xD;
          -  History of cerebrovascular accident, pulmonary embolism or untreated deep venous&#xD;
             thrombosis (DVT) within the past 6 months.&#xD;
&#xD;
          -  Prior major surgery or trauma within 28 days prior to first dose of investigational&#xD;
             product and/or presence of any non-healing wound, fracture, or ulcer&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding tendency.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Pazopanib</keyword>
  <keyword>GW786034</keyword>
  <keyword>Exemestane</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Health-Related Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

